# A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01017952** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 1635 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** FF/GW642444 Inhalation Powder
- **DRUG:** GW642444 Inhalation Powder

## Key facts

- **NCT ID:** NCT01017952
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-25
- **Primary completion:** 2011-10-01
- **Final completion:** 2011-10-17
- **Target enrollment:** 1635 (ACTUAL)
- **Last updated:** 2018-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017952, "A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01017952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*